Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine Manufacturers

By
Media Outreach
-
0
  • 87% of respondents deemed mRNA a key modality for the future
  • More than 60% vaccine makers surveyed plan revamp or new facilities for mRNA manufacturing to meet demand
  • Skilled personnel, tech-transfer expertise, reliable supply chain, and regulatory guidelines critical to new technology adoption

SINGAPORE – Media OutReach – 31 May 2023 – According to a recent study sponsored by Merck, a leading science and technology company, mRNA technology is a “game-changer” for Asia-Pacific (APAC) vaccine manufacturers. Nearly 40 manufacturers participated in the survey.

www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.